Lensless imaging for point-of-care testing

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1109/IEMBS.2009.5333765">http://dx.doi.org/10.1109/IEMBS.2009.5333765</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>Institute of Electrical and Electronics Engineers</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Accessed</td>
<td>Sat Dec 08 13:16:36 EST 2018</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/58814">http://hdl.handle.net/1721.1/58814</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td></td>
</tr>
</tbody>
</table>
Abstract—We show a platform that merges a microfluidic chip with lensless imaging for CD4+ T-lymphocyte counting at resource-limited settings. To capture CD4+ T-lymphocytes, anti-CD4 antibody was immobilized on a microfluidic chip. The captured cells were detected by a charge coupled device (CCD) sensor using lensless shadow imaging techniques. Gray scale shadow images of captured cells on the chip (24 mm × 4 mm × 50 μm) were enumerated in three seconds using an automatic cell counting software. The device achieved 70.2 ± 6.5% capture efficiency, 88.8 ± 5.4% capture specificity for CD4+ T-lymphocytes, 96 ± 1.6% CCD efficiency, and 83.5 ± 2.4% overall platform performance (n = 9 devices). This integrated platform has potential for point-of-care testing (POCT) to rapidly capture, image and count specific cell types from unprocessed whole blood.

I. INTRODUCTION

HIV remains the most serious infectious disease challenge to public health. As a result of inadequate access to HIV prevention and treatment, everyday, more than 6800 people contract HIV and more than 5700 people die from AIDS, globally[1]. In 2007, worldwide, 33.2 million people had HIV. 2.5 millions of these people were newly infected and 2.1 million died from AIDS. There is a lack of available monitoring technologies at resource limited settings. Blood cell isolation[2, 3] and enumeration methods are used to monitor progress of infectious diseases, such as HIV/AIDS[4]. Both CD4+ T-lymphocyte and viral load counts of patients have been used to monitor and initiate treatment of HIV disease using antiretroviral therapy (ART). ART is started for infected persons with CD4+ T-lymphocyte counts below 200 ~ 350 cells per microliter[4]. The CD4+ T-lymphocyte count is performed currently 3 ~ 4 times a year in the developed world, and twice a year in the developing world using fluorescent activated cell count and sorting systems (FACS)[5].

In resource limited settings, current advanced technologies such as FACSCount (Becton Dickinson, CA, USA) face a significant challenge to monitor or count thousands of cells because of equipment costs ($27,000), reagent costs ($5 ~ 20), limited throughput (30 ~ 50 samples/day), need for an experienced operator, and maintenance costs[6]. There is a need for rapid diagnostic and monitoring systems that are simple-to-use, inexpensive, reliable, and disposable enhancing current monitoring methods. There have been ideas to create smaller flowcytometers targeting global health and point-of-care applications with limited functionality such as Guava EasyCD4 assay[7]. However, the equipment costs about $35,000. There is a need to lower these costs even further for developing countries. Simple microfluidic approaches merged with rapid detection and counting could provide new avenues in this field.

Microfluidic chip and detection platform for infectious diseases could impact current global health problems[8]. These technologies could provide ease of use and minimal sample preparation steps for point-of-care testing (POCT)[9, 10]. To use microfluidic approaches to count CD4+ T-lymphocytes from whole blood, three significant challenges need to be addressed: (1) Capture and isolation of CD4+ cells from whole blood with a microfluidic chip in a high throughput manner. (2) Detecting the captured cells rapidly. We choose to develop a lensless CD4 cell detection system which we address in this paper. (3) Merging the microfluidic chip with a wide field-of-view (FOV) lensless imaging technology, and (4) rapid automated counting of cells from captured images. As a solution to the first challenge, it was earlier demonstrated that CD4+ T-lymphocytes can be captured selectively from whole blood using microfluidic channels by fluorescent labeling or label-free techniques[11-13]. CD4+ T-lymphocytes can be captured from whole blood either by mechanical filtering[13], or employing polydimethylsiloxane (PDMS) microfluidic devices with anti-CD4 antibody immobilization on channel surfaces[11]. These systems employ disposable microfluidic devices, but they require fluorescent labeling or long hours of counting under a microscope to determine CD4+ T-lymphocyte counts. Both approaches could be difficult to adopt for POCT at resource limited settings, since whole process needs to be performed in minutes rather than hours to be useful. This poses the following challenges to detect and quantify cells rapidly. As a first step to achieve the second challenge[14], cells free floating in microfluidic channels and placed between glass slides were detected by lensless cell shadow imaging. The key unresolved step that we demonstrate in this paper is to merge a properly fabricated microfluidic chip that can capture CD4 T cells from blood with a lensless imaging system that can detect captured cells in a channel. As a result, this platform provides a solution to
capture/detect CD4+ T-lymphocytes from blood samples. The last challenge is to rapidly enumerate the detected cells captured on the whole chip, which is performed by an automatic cell counting software. In this paper, we attack these challenges that are keys to develop a label-free lens-free CD4 T cell counting platform targeting resource limited settings.

Targeting the detection and counting challenges, there have been efforts to use electrodes integrated into microfluidic channels to indirectly quantify the number of cells using cell lysate electrical impedance[15] or using a local electric current change[16]. However, these methods may suffer from patient-to-patient variation, multiple wash steps, and low signal-to-noise levels. Instead of these indirect methods, recently direct cell detection methods through wide FOV have been developed such as lensless systems to image cells, (LUCAS: a lensless, ultra wide-field cell monitoring array platform based on shadow imaging)[14], to track Caenorhabditis elegans motion[17], and to detect antibody binding[18]. To have a platform system that achieves multiple functionalities of capture/detection/counting with whole blood comprises various additional integration difficulties such as, signal to noise ratio (SNR).

We focus on developing an integrated platform targeting point-of-care applications at resource-limited settings to count CD4+ T-lymphocytes from whole blood. We also present a method that creates microfluidic chips without using expensive photo-lithographical approaches. We demonstrate challenges and provide solutions to create an integrated platform that achieves sequentially; (i) selective rare cell capture on a microfluidic chip, (ii) detection of captured cells rapidly by a lensless CCD imaging platform, and (iii) automated cell counting to create an inexpensive system to enumerate CD4+ T-lymphocytes from blood samples.

We designed our chips as shown in fig. 1 and fabricated simply with a laser cutter instead of using expensive cleanroom equipment. Anti-CD4 antibody was immobilized on only one surface of the chip to capture the CD4 T lymphocytes. The microfluidic chip can be directly imaged with the CCD imaging platform and cells can be counted by automatic cell counting software. These steps take less than a minute. To image shadow patterns of captured cells with the CCD image sensor (KODAK, KAI-11002, Rochester, NY), the microchip was placed on the CCD surface. One gray color image of the entire channel surface was taken in one second. The sensor features more than 11 million square pixels (9 μm wide), across the active sensor array area, 37.25 mm × 25.70 mm, fig. 2. The large dimensions of the KODAK CCD chip allowed us to use commercially available microscope cover slides (24 mm × 35 mm × 0.10 mm). The white light, emitted by a halogen lamp (Micro-Lite, FL3000, Three Rivers, MA) with an annual light guide, passes through the PMMA cover and reaches the captured cells. A point white light source can be assumed as planar light source, if the light source is set up far from an object, i.e. a cell (fig 2a). Light intensity of a cell shadow image is determined by diffraction, which can be calculated by Rayleigh-Sommerfeld diffraction integral[14]. Fresnel number (N = πD2/4zλ) was used for determining whether our system was in diffraction (N > 1) or Fraunhofer region (N < 1). Our system operates in the Fraunhofer region (N = 0.1) with the following conditions: cell diameter (D = 10 μm), distance (z = 1.4 mm), and wavelength of light source (λ = 400 ~ 700 nm, white light). Although we operate in this region, the shadow image can be recognized by a CCD sensor. Figure 2c shows the entire channel image captured by a CCD after the cell capture process. Enlarged figure shows that the dark rings are from diffracted light forming the shadow cell images. When the distance between the cell and CCD surface was increased, the ring diameter of shadow image was enlarged. This effect was observed until SNR between the...
shadow and background light intensity reached to the detection limit of CCD pixels. Higher z values for our system (1.4 mm) is more beneficial for low CCD resolution, since it exaggerates the shadow image to larger than the actual cell size. An automatic cell counting software can resolve a threshold signal level, which determines the boundaries between cell membranes and background[19]. The CCD images were analyzed to count cells and characterize a distribution of captured cells as a function of distance from the channel inlet using the public domain NIH Image program.

II. RESULTS

Figure 3 show microfluidic chip capture specificity, capture efficiency, CCD efficiency, and overall platform performance. The average of nine devices was used to evaluate the efficiency and specificity of the CCD imaging platform. The chip specificity and efficiency are related to the surface chemistry and shear based mechanical filtration methods. The average value of the three blood samples shows 88.8 ± 5% capture specificity for CD4+ cells and 70.2 ± 6.7% capture efficiency (n = 9 devices).

The CCD efficiency was obtained by the ratio of CCD count and all captured cells, (CCD efficiency = CCD count / blue stained cell count). It indicates CCD imaging efficiency based on signal to noise ratio of imaged cells. We observed that CCD efficiency is 96 ± 1.6%. This high efficiency shows that the shadow diffraction image gives a sufficiently high signal to noise ratio.

CD4+ cell capture in the channel can be performed in less than 10 minutes including all the steps. After the cell capture step, it takes less than 20 seconds to get the CD4+ cell counts using the CCD cell counts (one second to capture the whole image of cells in the microfluidic channel, three seconds to run the automated cell counting software). This time budget is based on our experimental data. The enumeration time may be further reduced by employing smaller sample volumes (e.g., 5 µl of whole blood) without sacrificing the CD4 counting accuracy. Such a rapid CD4 count allows high throughput at resource-limited settings, when compared to existing systems (e.g., magnetic beads: 5 ~ 10 test per day) and flow cytometry (30 ~ 50 test per day, including incubation times for fluorescent cell staining)[20].

Further, this overall platform performance was defined by the ratio of CCD image count and absolute number of target cells obtained from gold standard, i.e. flow cytometry, (overall platform performance = CCD image count / gold standard). ‘Overall platform performance’ is the key descriptor of this device, since the CCD count “all cells” would be clinically used to estimate the CD4+ cell count. The overall platform performance was 83.5 ± 2.44 %. The repeatable performance and small standard deviation, ± 2.44 %, allow correcting for the length dependent count bias (in this case we divide by 0.835). The corrected CD4+ cell count estimate is clinically acceptable (± 10 % overall count error)[6].

III. CONCLUSIONS

We presented a novel method to build a point-of-care device that is merged with lensless imaging for rapid cell counting, i.e. CD4 counts. The lensless CCD imaging platform merged with label-free cell capture has potential for resource-limited settings, since it eliminates the need for fluorescent imaging; it reduces the time for cell capture, imaging, and counting to a few minutes from hours. The
integrated platform to merge the microchip with the CCD system was successful to capture, image and automatically count the CD4+ T-lymphocytes. This integrated system poses a promising future direction for point-of-care testing especially focusing on global health applications at resource limited settings.

ACKNOWLEDGMENT

Dr. Demirci would like to thank the Wallace H. Coulter Foundation for the Young Investigator in Bioengineering Award and CIMIT (Center for Integration of Medicine & Innovative Technology). The authors acknowledge NIH grant RO1 AI081534. Dr. Kuritzkes would like to acknowledge NIH grants RR016482 and AI060354 (Harvard University Center for AIDS Research).

REFERENCES


